UNASSIGNED: 5109 Background: To determine the @entity137 , tolerability and quality of life (QoL) of adjuvant CT with sequential RT in @entity1 (pts) with high-risk @entity1204 (hrec). METHODS: Pts with hrec from 8 institutions were enrolled. All pts underwent abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic (100%) and paraaortic (77%) lymphadenectomy and surgical staging. Pts received four cycles of @entity1311 175 mg/m   (P) and @entity3003 AUC5 (C) (d1, q21d), subsequent external pelvic radiation therapy (45 Gy: 1.8 Gy/d) and vaginal brachytherapy (15 Gy: 3x 5 Gy). QoL was assessed using the EORTC-QLQ-C30 questionnaire. Primary endpoints: tolerability, @entity137 and QoL. Secondary endpoint: progression-free survival (PFS). RESULTS: Thirty-five pts were enrolled from December 2004 through May 2008. Median follow-up was 21 months (range, 3-24 months). Most of the pts (n=30) had an endometroid histology. Distribution of @entity5 stage (FIGO 2006) was: Ic:9, IIa:2, IIb:5, IIIa:3 and IIIc:16. All pts received 4 cycles of P and C. All pts completed RT. Grade 3/4 hematologic @entity137 (in % of all cycles) were mild: @entity1210 6.6%, @entity3028 5.9%. Three cycles were delayed because of @entity1210 . Darbepoetin alfa was given in 5.1%, @entity1261 in 2.9%, blood transfusions in 2.9%. Grade 3/4 non-hematologic @entity137 were seldom (< 3%). Only, @entity1665 occurred in 44.8%. No overall change in QoL occurred during treatment. Median Global Health Score was 50%. 2-year progression-free survival was 77.1%. CONCLUSIONS: Adjuvant combination CT with P+C and sequential RT is well tolerated and a feasible regimen in pts with hrec.

Adjuvant sequential chemo-radiation therapy in high-risk XXXX : Results of a prospective, multicenter phase II study of the NOGGO.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial cancer'] @entity1665 :: ('MESH:D000505', 'Disease') :: ['alopecia'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['Carboplatin'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['Paclitaxel'] @entity3028 :: ('MESH:D000380', 'Disease') :: ['granulocytopenia'] @entity1210 :: ('MESH:C536227', 'Disease') :: ['leucopenia']
@entity1204 :: (MESH:D016889,Disease) :: ['endometrial cancer']
